🇺🇸 FDA

Intelligence · Clinical Pipeline

NEUROCRINE BIOSCIENCES Pipeline

All ClinicalTrials.gov programs at NEUROCRINE BIOSCIENCES — phase, modality, and trial IDs.

Programs
79

Quick answer

NEUROCRINE BIOSCIENCES has 79 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Chronocort®

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    5 trials

  2. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    4 trials

  3. Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  4. Hydrocortisone

    NEUROCRINE BIOSCIENCES INC

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    2 trials

  5. Identical to NBI-1065845 tablets without active drug, NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  6. Indiplon

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  7. Infacort®

    NEUROCRINE BIOSCIENCES INC

    Adrenal Insufficiency

    phase 3 small molecule completed

    4 trials

  8. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  9. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  10. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  12. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  13. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    5 trials

  14. NBI-1117568, NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  15. NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  16. NBI-34060

    NEUROCRINE BIOSCIENCES INC

    Insomnia

    phase 3 small molecule terminated

    1 trial

  17. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE BIOSCIENCES INC

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  18. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    6 trials

  19. Placebo

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  20. Placebo

    NEUROCRINE BIOSCIENCES INC

    Dyskinesia

    phase 3 small molecule completed

    1 trial

  21. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 3 small molecule completed

    2 trials

  22. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Chorea, Huntington

    phase 3 small molecule active

    3 trials

  23. Valbenazine, Valbenazine, Placebo for valbenazine capsules

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

  24. Chronocort

    NEUROCRINE BIOSCIENCES INC

    Primary Adrenal Insufficiency

    phase 2 small molecule completed

    1 trial

  25. Crinecerfont

    NEUROCRINE BIOSCIENCES INC

    CAH - Congenital Adrenal Hyperplasia

    phase 2 small molecule completed

    1 trial

  26. Hydrocortisone Modified Release Capsules

    NEUROCRINE BIOSCIENCES INC

    Endocrine Disease

    phase 2 small molecule completed

    1 trial

  27. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  28. NBI-1065890

    NEUROCRINE BIOSCIENCES INC

    Tardive Dyskinesia

    phase 2 small molecule active

    1 trial

  29. NBI-1070770

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  30. NBI-1117568

    NEUROCRINE BIOSCIENCES INC

    Bipolar I Disorder

    phase 2 small molecule active

    1 trial

  31. NBI-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  32. NBI-1117570, NBI-1117570, Placebo for nbi-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  33. NBI-5788

    NEUROCRINE BIOSCIENCES INC

    Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  34. NBI-74788

    NEUROCRINE BIOSCIENCES INC

    Congenital adrenal hyperplasia (CAH)

    phase 2 small molecule active

    1 trial

  35. NBI-74788

    NEUROCRINE BIOSCIENCES INC

    CAH - Congenital Adrenal Hyperplasia

    phase 2 small molecule completed

    1 trial

  36. NBI-827104

    NEUROCRINE BIOSCIENCES INC

    Epileptic Encephalopathy

    phase 2 small molecule terminated

    2 trials

  37. NBI-827104

    NEUROCRINE BIOSCIENCES INC

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  38. NBI-921352

    NEUROCRINE BIOSCIENCES INC

    SCN8A Developmental and Epileptic Encephalopathy Syndrome

    phase 2 small molecule active

    2 trials

  39. NBI-921352

    NEUROCRINE BIOSCIENCES INC

    Focal Onset Seizure

    phase 2 small molecule completed

    2 trials

  40. NBI-98854

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule terminated

    4 trials

  41. Placebo

    NEUROCRINE BIOSCIENCES INC

    Anhedonia

    phase 2 small molecule completed

    1 trial

  42. Placebo

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  43. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial

  44. TAK-831

    NEUROCRINE BIOSCIENCES INC

    Friedreich Ataxia

    phase 2 small molecule completed

    1 trial

  45. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Obsessive-Compulsive Disorder

    phase 2 small molecule active

    1 trial

  46. Valbenazine

    NEUROCRINE BIOSCIENCES INC

    Tourette Syndrome

    phase 2 small molecule completed

    4 trials

  47. Valbenazine Oral Capsule

    NEUROCRINE BIOSCIENCES INC

    Trichotillomania (Hair-Pulling Disorder)

    phase 2 small molecule active

    1 trial

  48. interleukin-4 PE38KDEL cytotoxin

    NEUROCRINE BIOSCIENCES INC

    Brain and Central Nervous System Tumors

    phase 2 mab completed

    1 trial

Frequently asked questions

How many pipeline programs does NEUROCRINE BIOSCIENCES have?

79 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.